

NEWS

NOT FOR IMMEDIATE RELEASE

Clinical Data, Inc. Signs Contract with Blue Cross and Blue Shield Association for National Access to *FAMILION*[®] Genetic Tests for Inherited Cardiac Syndromes

NEWTON, Mass. – February 10, 2009 – PGxHealth, a division of Clinical Data, Inc. (NASDAQ: CLDA), announced today that it has executed a contract with Blue Cross and Blue Shield Association (BCBSA) that will provide individual Blue Cross and Blue Shield companies with access to the *FAMILION* Long QT Syndrome (LQTS) genetic tests for inherited cardiac syndromes. Each of the 39 separate Blue Cross and Blue Shield companies, acting independently, now has the opportunity to enter into an ancillary contract to access *FAMILION* LQTS tests for its members, as each Blue company may deem fit. The *FAMILION* LQTS tests are used to detect an inherited form of cardiac disease, Long QT Syndrome. By detecting genetic mutations in certain individuals and their families, when medically necessary, the *FAMILION* LQTS tests can help to guide treatment decisions and may prevent possible sudden cardiac death.

“This contract represents a significant achievement for PGxHealth and we look forward to working with the Blue Cross and Blue Shield companies to obtain coverage for our *FAMILION* tests,” said Jim Shaffer, Vice President, Sales and Marketing of PGxHealth.

PGxHealth is an approved Medicare provider for its genetic testing services, and a Medicaid provider in 38 states and the District of Columbia. These providers and other private payers with positive coverage policies offer access to genetic testing for nearly 200 million patients. The positive changes to the reimbursement landscape for PGxHealth’s genetic tests demonstrate the Company’s commitment to working with private and government payers to improve patient access to these vital tests.

For More Information on the *FAMILION* LQTS tests contact PGxHealth Customer Service at 877-2-PGxHealth (877-274-9432) or visit its Web site at www.pgxhealth.com.

About *FAMILION*[®]

The *FAMILION* tests detect genetic mutations that can cause cardiac channelopathies or cardiomyopathies such as Long QT Syndrome (LQTS), Brugada Syndrome (BrS), Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), Hypertrophic Cardiomyopathy (HCM), and Arrhythmic Right Ventricular Cardiomyopathy (ARVC) in individuals and their families. For more information about the *FAMILION* family of genetic tests, visit www.pgxhealth.com/genetictests/familion.

By detecting genetic mutations, the *FAMILION* tests can be used to recognize inherited forms of these syndromes, helping to guide treatment and reduce the incidence of deadly cardiac events associated with them. When a cardiac channelopathy or cardiomyopathy has been diagnosed, the test can help doctors and patients make more informed treatment decisions and aid in uncovering other family members that may be at risk, even if asymptomatic.

About PGxHealth

PGxHealth, a division of Clinical Data, Inc, is utilizing its biomarker expertise and intellectual property to develop and commercialize targeted therapeutics as well as pharmacogenetic tests that detect serious diseases and help predict drug safety and efficacy. By using innovative technologies and working with some of the world's most prestigious genomics thought leaders and institutions, PGxHealth is focused on reducing treatment costs and improving clinical outcomes in disease states and therapeutic classes with expensive, inefficient or suboptimal treatment options. Among its tests are the *FAMILION*[®] and the PGxPredict[®] brands. Please visit the website at www.pgxhealth.com.

About Clinical Data, Inc.

Clinical Data is a global biotechnology company unlocking the potential of molecular discovery, *From Targeted Science to Better Healthcare*[®]. The Company's PGxHealth[®] division is utilizing its proprietary portfolio of biomarkers to develop and commercialize a broad range of targeted therapeutics as well as pharmacogenetic tests that help predict drug safety and efficacy, thereby reducing health care costs. Its Cogenics[®] division provides genomics services to both research and regulated environments. Through these divisions, Clinical Data is leveraging advances in molecular discovery to provide tangible benefits for patients, doctors, scientists and health plans worldwide. To learn more, please visit the Company's website at www.clda.com.

CONTACT INFORMATION:

Theresa McNeely
Vice President
Corporate Communications
Clinical Data, Inc.
617-527-9933 x 3373

General Business Inquiries

617-527-9933 x 3388

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains certain forward-looking information and statements that are intended to be covered by the safe harbor for forward looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)", "feel(s)", "believe(s)", "will", "may", "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements about our ability to successfully integrate the operations, business, technology and intellectual property obtained in our acquisitions; our ability to obtain regulatory approval for, and successfully introduce our new products; our ability to expand our long-term

business opportunities; financial projections and estimates and their underlying assumptions; and statements regarding future performance. All of such information and statements are subject to certain risks and uncertainties, the effects of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to, whether our PGxPredicti[®] tests, including but not limited to FAMILION, will gain wide acceptance in the market; the extent to which genetic markers are predictive of clinical outcomes and drug efficacy and safety; the strength of our intellectual property rights; competition from pharmaceutical, biotechnology and diagnostics companies; the development of and our ability to take advantage of the market for pharmacogenetic and biomarker products and services; whether Clinical Data will be able to develop or acquire additional products and attract new business and strategic partners; and those risks identified and discussed by Clinical Data in its filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward looking statements that speak only as of the date hereof. Clinical Data does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures in Clinical Data's SEC periodic and interim reports, including but not limited to its Annual Report on Form 10-K for the fiscal year ended March 31, 2008, Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2008, and Current Reports on Form 8-K filed from time to time by the Company.

###